Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated with Tuberous Sclerosis Complex (TSC
A new clinical trial for individuals with TSC and facial angiofibromas who are 6 – 65 years old. Individuals who have used oral rapamycin/sirolimus, everolimus, or temsirolimus within 3 months of enrollment or have had laser surgery within 6 months of enrollment are not eligible to participate.
These locations in the United States are recruiting participants:
University of California San Diego
La Jolla, California, United States, 92037
Contact: Jessica Reit email@example.com
Principal Investigator: Doris Trauner
Grand Rapids, Michigan, United States, 49503
Contact: Christopher L Russell firstname.lastname@example.org
Principal Investigator: Steven DeRoos
Rochester, Minnesota, United States, 55905
Contact: Katrina Pierce, CCRP 507-266-1078 email@example.com
Principal Investigator: Megha M Tollefson, MD
Sub-Investigator: Lily C Wong-Kisiel, MD
For more information go to ClinicalTrial.gov.